schliessen

Filtern

 

Bibliotheken

Dominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling

OBJECTIVE—: The peroxisome proliferator activated receptor-gamma (PPARγ) protein is a nuclear transcriptional activator with importance in diabetes management as the molecular target for the thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of PPARγ agonists... Full description

Journal Title: Arteriosclerosis Thrombosis, and Vascular Biology, 2009, Vol.29(4), pp.465-471
Main Author: Meredith, J., Dane
Other Authors: Panchatcharam, A., Manikandan , Miriyala, S., Sumitra , Tsai, S., Yau-Sheng , Morris, S., Andrew , Maeda, S., Nobuyo , Stouffer, S., George , Smyth, S., Susan
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1079-5642 ; DOI: 10.1161/ATVBAHA.109.184234
Link: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-200904000-00008
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ovid00043605-200904000-00008
title: Dominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
format: Article
creator:
  • Meredith, J., Dane
  • Panchatcharam, A., Manikandan
  • Miriyala, S., Sumitra
  • Tsai, S., Yau-Sheng
  • Morris, S., Andrew
  • Maeda, S., Nobuyo
  • Stouffer, S., George
  • Smyth, S., Susan
subjects:
  • Medicine
ispartof: Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, Vol.29(4), pp.465-471
description: OBJECTIVE—: The peroxisome proliferator activated receptor-gamma (PPARγ) protein is a nuclear transcriptional activator with importance in diabetes management as the molecular target for the thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of PPARγ agonists may retard the development of atherosclerosis. However, recent clinical data have suggested that at least one TZD may increase the risk of myocardial infarction and death from cardiovascular disease. In this study, we used a genetic approach to disrupt PPARγ signaling to probe the proteinʼs role in smooth muscle cell (SMC) responses that are important for atherosclerosis. METHODS AND RESULTS—: SMC isolated from transgenic mice harboring the dominate-negative P465L mutation in PPARγ (PPARγ) exhibited greater proliferation and migration then did wild-type cells. Upregulation of ETS-1, but not ERK activation, correlated with enhanced proliferative and migratory responses PPARγ SMCs. After arterial injury, PPARγ mice had a ≈4.3-fold increase in the development of intimal hyperplasia. CONCLUSION—: These findings are consistent with a normal role for PPARγ in inhibiting SMC migration and proliferation in the context of restenosis or atherosclerosis.
language:
source:
identifier: ISSN: 1079-5642 ; DOI: 10.1161/ATVBAHA.109.184234
fulltext: fulltext
issn:
  • 1079-5642
  • 10795642
url: Link


@attributes
ID676871843
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid00043605-200904000-00008
sourceidovid
recordidTN_ovid00043605-200904000-00008
sourceformatXML
sourcesystemPC
pqid67057997
display
typearticle
titleDominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
creatorMeredith, J., Dane ; Panchatcharam, A., Manikandan ; Miriyala, S., Sumitra ; Tsai, S., Yau-Sheng ; Morris, S., Andrew ; Maeda, S., Nobuyo ; Stouffer, S., George ; Smyth, S., Susan
ispartofArteriosclerosis, Thrombosis, and Vascular Biology, 2009, Vol.29(4), pp.465-471
identifierISSN: 1079-5642 ; DOI: 10.1161/ATVBAHA.109.184234
descriptionOBJECTIVE—: The peroxisome proliferator activated receptor-gamma (PPARγ) protein is a nuclear transcriptional activator with importance in diabetes management as the molecular target for the thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of PPARγ agonists may retard the development of atherosclerosis. However, recent clinical data have suggested that at least one TZD may increase the risk of myocardial infarction and death from cardiovascular disease. In this study, we used a genetic approach to disrupt PPARγ signaling to probe the proteinʼs role in smooth muscle cell (SMC) responses that are important for atherosclerosis. METHODS AND RESULTS—: SMC isolated from transgenic mice harboring the dominate-negative P465L mutation in PPARγ (PPARγ) exhibited greater proliferation and migration then did wild-type cells. Upregulation of ETS-1, but not ERK activation, correlated with enhanced proliferative and migratory responses PPARγ SMCs. After arterial injury, PPARγ mice had a ≈4.3-fold increase in the development of intimal hyperplasia. CONCLUSION—: These findings are consistent with a normal role for PPARγ in inhibiting SMC migration and proliferation in the context of restenosis or atherosclerosis.
source
subjectMedicine;
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-200904000-00008$$EView_record_at_Wolters_Kluwer_Health_Ovid_Technologies
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutOvid.html$$EView_Wolters_Kluwer_Health,_Lippincott,_Williams_&_Wilkins_Copyright_Statement
search
creatorcontrib
0Meredith, J, Dane
1Panchatcharam, A, Manikandan
2Miriyala, S, Sumitra
3Tsai, S, Yau-Sheng
4Morris, S, Andrew
5Maeda, S, Nobuyo
6Stouffer, S, George
7Smyth, S, Susan
titleDominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
descriptionOBJECTIVE—: The peroxisome proliferator activated receptor-gamma (PPARγ) protein is a nuclear transcriptional activator with importance in diabetes management as the molecular target for the thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of PPARγ agonists may retard the development of atherosclerosis. However, recent clinical data have suggested that at least one TZD may increase the risk of myocardial infarction and death from cardiovascular disease. In this study, we used a genetic approach to disrupt PPARγ signaling to probe the proteinʼs role in smooth muscle cell (SMC) responses that are important for atherosclerosis. METHODS AND RESULTS—: SMC isolated from transgenic mice harboring the dominate-negative P465L mutation in PPARγ (PPARγ) exhibited greater proliferation and migration then did wild-type cells. Upregulation of ETS-1, but not ERK activation, correlated with enhanced proliferative and migratory responses PPARγ SMCs. After arterial injury, PPARγ mice had a ≈4.3-fold increase in the development of intimal hyperplasia. CONCLUSION—: These findings are consistent with a normal role for PPARγ in inhibiting SMC migration and proliferation in the context of restenosis or atherosclerosis.
general
010.1161/ATVBAHA.109.184234
1© 2009 American Heart Association, Inc.
2Lippincott Williams & Wilkins - Journals
sourceidovid
recordidovid00043605-200904000-00008
issn
01079-5642
110795642
rsrctypearticle
creationdate2009
addtitleArteriosclerosis, Thrombosis, and Vascular Biology
searchscopeovid
scopeovid
lsr30VSR-Enriched:[pqid, eissn, subject]
sort
titleDominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
authorMeredith, J., Dane ; Panchatcharam, A., Manikandan ; Miriyala, S., Sumitra ; Tsai, S., Yau-Sheng ; Morris, S., Andrew ; Maeda, S., Nobuyo ; Stouffer, S., George ; Smyth, S., Susan
creationdate20090400
facets
frbrgroupid6686861360787110982
frbrtype5
newrecords20170719
creationdate2009
collectionLippincott Williams & Wilkins Journals (Wolters Kluwer Health)
prefilterarticles
rsrctypearticles
creatorcontrib
0Meredith, J., Dane
1Panchatcharam, A., Manikandan
2Miriyala, S., Sumitra
3Tsai, S., Yau-Sheng
4Morris, S., Andrew
5Maeda, S., Nobuyo
6Stouffer, S., George
7Smyth, S., Susan
jtitleArteriosclerosis, Thrombosis, and Vascular Biology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Meredith
1Panchatcharam
2Miriyala
3Tsai
4Morris
5Maeda
6Stouffer
7Smyth
aufirst
0Dane
1Manikandan
2Sumitra
3Yau-Sheng
4Andrew
5Nobuyo
6George
7Susan
auinitm
0J.
1A.
2S.
au
0Meredith, J., Dane
1Panchatcharam, A., Manikandan
2Miriyala, S., Sumitra
3Tsai, S., Yau-Sheng
4Morris, S., Andrew
5Maeda, S., Nobuyo
6Stouffer, S., George
7Smyth, S., Susan
atitleDominant-Negative Loss of PPARγ Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling
jtitleArteriosclerosis, Thrombosis, and Vascular Biology
risdate200904
volume29
issue4
spage465
epage471
pages465-471
issn1079-5642
formatjournal
genrearticle
ristypeJOUR
abstractOBJECTIVE—: The peroxisome proliferator activated receptor-gamma (PPARγ) protein is a nuclear transcriptional activator with importance in diabetes management as the molecular target for the thiazolidinedione (TZD) family of drugs. Substantial evidence indicates that the TZD family of PPARγ agonists may retard the development of atherosclerosis. However, recent clinical data have suggested that at least one TZD may increase the risk of myocardial infarction and death from cardiovascular disease. In this study, we used a genetic approach to disrupt PPARγ signaling to probe the proteinʼs role in smooth muscle cell (SMC) responses that are important for atherosclerosis. METHODS AND RESULTS—: SMC isolated from transgenic mice harboring the dominate-negative P465L mutation in PPARγ (PPARγ) exhibited greater proliferation and migration then did wild-type cells. Upregulation of ETS-1, but not ERK activation, correlated with enhanced proliferative and migratory responses PPARγ SMCs. After arterial injury, PPARγ mice had a ≈4.3-fold increase in the development of intimal hyperplasia. CONCLUSION—: These findings are consistent with a normal role for PPARγ in inhibiting SMC migration and proliferation in the context of restenosis or atherosclerosis.
pub© 2009 American Heart Association, Inc.
doi10.1161/ATVBAHA.109.184234
eissn15244636
date2009-04